AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).
- AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).
- The regulatory review and device registration was conducted by Singapore’s Health Sciences Authority (hereinafter HSA) on February 19, 2024.
- The endoscopic AI (hereinafter gastric cancer differentiation AI) differentiates gastric lesions and judges them as either neoplastic or non-neoplastic in nature.
- In countries with a high incidence of gastric cancer like Japan and South Korea, endoscopic gastric cancer screening is routinely performed nationwide.